IGLV2-5

Across TCGA pan-cancer cohorts, IGLV2-5 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGLV2-5’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where IGLV2-5 RNA is repressed in tumor relative to normal tissue. In most cancer types IGLV2-5 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.

COAD, LUAD, and READ are the cancer types where IGLV2-5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLV2-5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	−1.279	<.001	9	view →
LUAD	Female	All	+1.122	<.001	9	view →
READ	All	All	−1.708	<.001	7	view →
BRCA	Female	All	−0.396	.001	4	view →
KIRC	All	All	+0.376	<.001	4	view →
STAD	Male	IV	−5.180	.002	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IGLV2-5–COAD

Open the COAD breakdown →